Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762266 · ClinicalTrials.gov registry record · Phase 3
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
A Phase 3 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02762266: Clinical Trial Phase 3 study, sponsored by Stanford University.
NCT02762266 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02762266, a Phase 3 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer that remain after attempts to remove the cancer have been made (residual) or has come back (recurrent). TACE is a minimally invasive, image-guided treatment procedure that uses a catheter to deliver both chemotherapy medication and embolization materials into the blood vessels that lead to the tumors. SBRT or SABR may be able to send radiation directly to the tumor and cause less damage to normal liver tissue. It is not yet known whether TACE is more effective than SBRT or SABR in treating patients with persistent or recurrent liver cancer who have undergone initial TACE.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- PROCEDURE Transarterial Chemoembolization
- DRUG embolic agent
- DRUG lipiodol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-02-27 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762266
The ClinicalTrials.gov registry entry for NCT02762266 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT02762266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762266 about?
NCT02762266 is a clinical study titled "Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization". This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer that remain after attempts to remove the cancer have been made (residua...
What is the current status of trial NCT02762266?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2016-02-27. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02762266?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Transarterial Chemoembolization (PROCEDURE), embolic agent (DRUG), lipiodol (DRUG).
Who is sponsoring clinical trial NCT02762266?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.